Status:
COMPLETED
Diagnostic Value and Safety of Flecainide Infusion Test in Brugada Syndrome
Lead Sponsor:
NYU Langone Health
Conditions:
Brugada Syndrome
Arrhythmogenic Right Ventricular Cardiomyopathy
Eligibility:
All Genders
18-75 years
Brief Summary
The study aims to use flecainide infusion test as diagnostic test to unmask concealed Brugada Syndrome cases. It proposes to assess the safety profile of this test in US patients and its higher sensit...
Detailed Description
Brugada Syndrome is an inherited arrhythmogenic disease responsible for life-threatening arrhythmias and sudden cardiac death in young individuals with structural normal heart. It is characterized by...
Eligibility Criteria
Inclusion
- Suspect diagnosis of Brugada Syndrome or ARVC
- Idiopathic ventricular fibrillation and suspect concealed Brugada syndrome
- Family history of Brugada Syndrome
- Family history of unexpected cardiac sudden death
Exclusion
- Type 1 Brugada Syndrome ECG
- Pregnancy
- History and/or evidence of ischemic cardiomyopathy
- Recent myocardial infarction
- Allergy or known adverse reaction to flecainide
Key Trial Info
Start Date :
July 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 26 2017
Estimated Enrollment :
209 Patients enrolled
Trial Details
Trial ID
NCT02302274
Start Date
July 1 2010
End Date
July 26 2017
Last Update
April 18 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
New york University, School of Medicine
New York, New York, United States, 10010